Baird raised the price target for the Alkermes plc (NASDAQ:ALKS) stock to “an Outperform”. The rating was released on March 19, 2024, according to finviz. The research report from JP Morgan has ...

Alkermes (NASDAQ:ALKS) has been analyzed by 6 analysts in the last three months, revealing a diverse range of perspectives ...

Investors need to pay close attention to About Alkermes (ALKS) stock based on the movements in the options market lately.

Market OverviewThe Addiction Rehab Facilities Market, valued at USD 16.8 billion in 2023, is anticipated to experience substantial growth, reaching about USD 31.3 billion by 2032. This growth ...

Alkermes is positioned for outperformance due to its conservative cash-heavy balance sheet and high-margin business model.

The price-to-earnings ratio for Alkermes plc (NASDAQ:ALKS) is 9.65. The price-to-earnings ratio is a method of assessing corporate values by comparing them to their per-share profit. Forward P/E ...

The Global Schizophrenia Drugs Market is projected to grow significantly, with an expected market size of USD 12.6 billion by 2032, up from USD 7.4 billion in 2022, at a compound annual growth rate ...

Alkermes plc (Nasdaq: ALKS) today announced the presentation of research related to its psychiatry franchise ...

Alkermes plc last week announced it had completed the sale of its development and manufacturing facility in Athlone, to Novo Nordisk. The Chief Executive Officer of Alkermes, Richard Pops, paid ...

The volatility ratio for the week is 2.98%, and the volatility levels for the last 30 days are 2.94% for Alkermes plc The simple moving average for the past 20 days is 0.53% for ALKS’s stock, with a ...

Throughout the last three months, 7 analysts have evaluated Alkermes ALKS, offering a diverse set of opinions from bullish to bearish. The table below provides a concise overview of recent ratings ...